Ligand Pharmaceuticals Inc.
LGNDLigand Pharmaceuticals Inc. (LGND) is a biopharmaceutical company that focuses on the development and acquisition of technology platforms and proprietary products for the advancement of innovative medicines. The company partners with other pharmaceutical firms to develop and commercialize drug candidates, leveraging its expertise in biology, chemistry, and process development to streamline drug discovery and development.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 1, 2010 | $0.08 | 2010-07-02 | 2010-06-28 |
| April 19, 2007 | $2.50 | 2007-04-03 | 2007-04-05 |
Dividends Summary
- Consistent Payer: Ligand Pharmaceuticals Inc. has rewarded shareholders with 2 dividend payments over the past 3 years.
- Total Returned Value: Investors who held LGND shares during this period received a total of $2.58 per share in dividend income.
- Latest Payout: The most recent dividend of $0.08/share was paid 5861 days ago, on July 1, 2010.
- Dividend Growth: Since 2007, the dividend payout has decreased by 96.9%, from $2.50 to $0.08.
Company News
As tech stocks cool and market concentration risks increase, investors should diversify into overlooked sectors. Healthcare, insurance, and regional banking are quietly building momentum. Three recommended stocks are Ligand Pharmaceuticals (royalty-based biotech model with strong growth projections), Aflac (insurance with 44-year dividend history...
The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. ...
XOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July...
Ligand Pharmaceuticals announced it will host an Investor Day in New York City on December 8, 2026, featuring presentations from senior management on the company's strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast will be available through the company's Investor Relations website.
Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold 5,000 shares worth approximately $1.14 million on June 1, 2026, through the exercise and immediate disposition of stock options. Post-transaction, Reardon retains 41,382 shares and 39,444 employee stock options. The analyst views this as income supplementation rather than a loss of c...
